vinflunine,docetaxel,erdafitinib,pembrolizumab
pierre fabre,merck,janssen
[' uc,(-ucsd),(-ucsf),', 'erdafitinib', 'thor study']
the thor study: erdafitinib vs chemo in pretreated advanced fgfr+ve uc=os benefit (hr=0.64,rr 45%). sfx different from chemo needing experience. strong data + level 1a evidence = a global standard of care imo. different populations means comparisons with ev are futile. #asco2023 
Interested in Urology Cancers, biomarkers and drug development.